Suciraslimab
Suciraslimab (SM03) is an anti-human CD22 monoclonal antibody. Suciraslimab inhibits NLRP3 and ASC signaling. Suciraslimab suppresses cytokine (IL-1β, IL-12, IL-23) secretion and α4 integrin expression. Suciraslimab improves working memory and neuroinflammation[1]. Suciraslimab isotype control product: Human IgG1 kappa, Isotype Control (HY-P99001) .
Product Specifications
CAS Number
[2415439-63-1]
Product Name Alternative
SM03
UNSPSC
12352203
Target
CD22; Integrin; Interleukin Related; NOD-like Receptor (NLR)
Type
Inhibitory Antibodies
Related Pathways
Cytoskeleton; Immunology/Inflammation
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology; Neurological Disease
Assay Protocol
https://www.medchemexpress.com/suciraslimab.html
Purity
97.42
Smiles
[Suciraslimab]
Molecular Weight
(146.16 kDa)
References & Citations
[1]Mai YD, et al. CD22 modulation alleviates amyloid β-induced neuroinflammation. J Neuroinflammation. 2025 Feb 5;22 (1) :32.
Shipping Conditions
Dry Ice
Storage Conditions
-80°C
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 3
Isoform
IL-1; IL-12; IL-23
Available Sizes
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
Recombinant Human Receptor-type tyrosine-protein phosphatase epsilon (PTPRE)
